ESTRO 2025 - Abstract Book

S1282

Clinical – Lower GI

ESTRO 2025

1 Department of Oncotherapy, University of Szeged, Szeged, Hungary. 2 County Center of Clinical Oncology and Radiotherapy, Békés County Central Hospital, Gyula, Hungary. 3 Department of Pathology, University of Szeged, Szeged, Hungary. 4 Department of Radiology, University of Szeged, Szeged, Hungary. 5 Department of Surgery, University of Szeged, Szeged, Hungary. 6 Department of Internal Medicine, University of Szeged, Szeged, Hungary Purpose/Objective: This study aimed to evaluate our experience with total neoadjuvant therapy (TNT), which sequentially combines radiation therapy (RT) or chemo-radiotherapy (ChRT) with chemotherapy (ChT) during the preoperative oncological management of high-risk locally advanced rectal cancer (LARC). Material/Methods: We retrospectively analyzed data of patients who received TNT at the Department of Oncotherapy, University of Szeged, between January 1, 2020, and January 30, 2024. Inclusion criteria included histologically confirmed rectal adenocarcinoma, no evidence of distant metastases on chest-abdominopelvic CT, diagnosis of resectable LARC with at least one risk factor (cT3c-d-T4, cN2, EMVI+, CRM+), by rectal MRI, based on multidisciplinary team decision. Patients received either neoadjuvant short-course (SC) RT (25Gy/5 fractions, mainly during the COVID-19 pandemic) or long-course (LC) ChRT (50.4 Gy/28 fractions+2x825 mg/m2 capecitabine) followed by 3 months of CAPOX ChT before surgery.

Results: